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Abstract		
Lysosomal	storage	disorders	(LSDs)	are	rare	inherited	debilitating	and	often	fatal	disorders.	Caused	
by	mutations	 of	 lysosomal	 proteins,	 they	 are	 characterized	 by	 the	 accumulation	 of	 undegraded	
material	in	lysosomes	and	by	lysosomal	dysfunction.	While	the	LSDs	are	multisystemic	diseases,	the	
majority	 present	 neurologic	 symptoms	 and	 neurodegeneration.	 Only	 very	 recently	 has	 a	 role	
emerged	for	mitochondrial	dysfunction	in	the	pathophysiology	of	some	LSDs,	suggesting	a	direct	or	
indirect	impact	of	lysosomal	dysfunction	on	mitochondria.	Moreover,	mitochondrial	damage	may	
also	cause	lysosomal	dysfunction,	further	supporting	the	activity	of	common	signaling	pathways	and	
cross-talk	between	the	two	organelles.	Thus,	the	interface	between	lysosomal	and	mitochondrial	
(dys)function	is	emerging	as	an	important	contributor	to	the	pathogenesis	of	the	LSDs	and	other	
neurodegenerative	 disorders.	 In	 this	 review,	we	 explore	 the	mechanisms	 linking	 lysosomal	 and	
mitochondrial	dysfunction,	in	order	to	assess	whether	specific	mitochondrial	pathways	represent	a	
new	therapeutic	frontier	in	the	management	of	the		LSDs.		
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Etiopathogenesis	of	Lysosomal	Storage	Disorders		
Lysosomal	storage	disorders	 (LSD)	are	a	class	of	more	than	50	rare	 inherited	metabolic	diseases	
caused	by	 genetic	mutations	 in	 either	 lysosomal	 enzymes,	 non-enzymatic	 lysosomal	 proteins	 or	
non-lysosomal	proteins,	affecting	lysosomal	function.	The	loss	of	function	of	these	proteins	leads	to	
accumulation	 of	 storage	 material	 in	 the	 endosomal,	 autophagic	 and/or	 lysosomal	 systems,	
influencing		a	number	of	cell	signaling	pathways	and	reducing	cell	survival	[1].		
The	combined	frequency	of	all	LSDs	is	estimated	to	be	between	1	in	5000	and	1	in	7500	live	births	
in	many	population	studies	[2,3],	but	may	be	higher,	as	a	number	of	children	are	likely	misdiagnosed	
or	undiagnosed.	A	number	of	different	clinical	presentations	have	been	described	for	each	LSD,	with	
variable	symptoms,	severity,	age	of	onset,	as	well	as	prognosis.		
Different	 LSDs,	 such	 as	Gaucher’s	 disease	 (GD),	Niemann	Pick	disease	C	 (NPC),	Neuronal	 Ceroid	
Lipofuscinosis	(NCL)	or	Mucopolysaccharidosis	(MPS),	tend	to	affect	different	organ	systems.	The	
majority	of	LSDs	--but	not	all	--	have	a	profound	impact	on	the	central	nervous	system	(CNS)	and	
can	affect	multiple	brain	regions	 leading	to	neurodegeneration	(see	Box	1).	 In	 fact,	LSDs	are	the	
major	 cause	 of	 neurodegeneration	 in	 childhood	 at	 least	 in	 the	 United	 Kingdom	 [4].	 As	 current	
treatments	are	broadly	ineffective	for	various	neurologic	symptoms	[5],	there	is	an	urgent	need	for	
new	therapeutic	strategies	and	for	the	development	of	drugs	that	can	effectively	target	affected	
brain	regions	(see	Box	2).	
Since	LSDs	are	individually	rare	disorders,	the	idea	that	common	underlying	mechanisms	may	help	
to	define	common	clinical	approaches	to	treat	different	LSDs	is	particularly	appealing.	Moreover,	
interest	 in	 these	 diseases	 has	 recently	 grown,	 as	 new	 studies	 have	 highlighted	 shared	 signaling	
pathways	that	seem	to	underlie	neurodegeneration	in	both	the	LSDs	and	more	common	and	more	
extensively	 studied	neurodegenerative	disorders,	 including	Alzheimer’s	and	Parkinson’s	Diseases	
[6–9].	For	example,	Parkinson’s	disease	(PD)	has	strong	links	with	GD	(Box	1).	Indeed,	heterozygous	
mutations	 in	 the	 lysosomal	 enzyme	 glucocerebrosidase	 (GCase,	 encoded	 by	 the	 gene	GBA1),	 --	
otherwise	associated	with	GD--	are	the	major	known	genetic	risk	factor	for	PD	[10].	Moreover,	(ii)	
the	protein	alpha-synuclein	(aS),	strongly	associated	with	Parkinson’s	Disease,	 	also	accumulates	
and	 is	 aggregated	 in	GD	animal	models	and	 in	GD	patients	 [11–14].	And	 lastly,	 for	 reasons	 that	
remain	obscure,	GCase	activity	is	reduced	in	the	brains	of	patients	with	sporadic	PD	[15].	Common	
genetic	deficiencies	between	LSDs	and	neurdegenerative	disorders	[8,10],	involvement	of	proteins	
associated	with	 PD	 and	 AD	 etiopathogenesis	 [6,9,12,14]	 and	 common	 impaired	mechanisms	 as	
autophagy-lysosomal	pathway	or	mitochondrial	dysfunction	[7,9,16]	are	new	lines	of	research	that	
	 3	
deserve	 special	 attention.	 In	 fact,	 comparing	 the	 similarities	 and	 differences	 between	 LSDs	 and	
other	 neurodegenerative	 disease	 groups	may	 help	 elucidate	 further	 the	molecular	mechanisms	
underlying	 the	 pathogenesis	 of	 the	 LSDs	 and	 consequently,	 facilitate	 the	 development	 of	 novel	
therapeutic	 approaches	 to	 treat	 these	 debilitating	 conditions.	 In	 this	 review,	 we	 will	 therefore	
compare	 mitochondrial	 dysfunctions	 in	 different	 LSDs	 models	 and	 discuss	 their	 causes	 and	
consequences	 ranging	 from	 mitophagy	 impairment,	 increased	 ROS	 production,	 calcium	
dysregulation,	 with	 a	 special	 mention	 to	 the	 contribution	 of	 aS	 aggregation	 to	 mitochondrial	
damage.		
The	Dialogue	between	Mitochondrial	and	Lysosomal	Function	
The	functional	integrity	of	lysosomes	and	mitochondria	is	critically	important	for	their	roles	in	cell	
physiology	and	for	the	maintenance	of	cell	‘health’	(see	Box	3	and	4,	respectively).	In	non-mitotic	
cells,	degradation	of	material	by	 lysosomes	 is	especially	 crucial,	because	 the	 lack	of	 cell	division	
prevents	the	dilution	of	molecules	that	accumulate	in	the	cytoplasm.	Mitochondrial	function	is	also	
particularly	 important	 in	 neurons	 which	 have	 a	 limited	 capacity	 to	 upregulate	 glycolytic	 ATP	
generation	and	are	therefore	dependent	on	oxidative	phosphorylation	for	their	energy	supply	[17].	
Strong	 links	 between	mitochondria	 and	 lysosomal	 biology	 are	 emerging.	 Lysosomes	 play	 a	 very	
important	 role	 in	 most	 of	 the	 processes	 that	 allow	 removal	 of	 dysfunctional	 mitochondria	
(mitophagy).	Moreover,	Mitochondrial	Derived	Vesicles	 (MDVs)	are	vesicular	 carriers	 in	 the	cell	
cytoplasm	which	move	mitochondrial	components	to	other	organelles	and	constitute	an	 integral	
part	of	the	mitochondrial	quality	control	systems	which	remove	from	the	mitochondrial	pool	those	
that	are	damaged,	even	carrying	selected	mitochondrial	cargoes	to	lysosomes	for	degradation	in	
HeLa	cells	[18].		
Activation	of	the	lysosomal	transcription	factor	EB	(TFEB)	(promoting	lysosomal	biogenesis	–	see	
text	Box	3)	proved	sufficient	to	restore	mitochondrial	membrane	potential	and	ATP	production	in	
human	induced	Pluripotent	Stem	Cell	(iPSC)	derived	neurons	in	which		mitochondrial	function	was	
compromised	following	long	term	treatment	with	rotenone,	(which	inhibits	mitochondrial	complex	
I	 )	 [19].	 TFEB	 overexpression	 by	 adenovirus	 injection	 lead	 also	 to	 a	 significant	 upregulation	 of	
peroxisome	 proliferator-activated	 receptor	 γ	 coactivator	 1	 α	 (PGC1α)	 in	 mice	 liver	 during	
starvation	 [20].	 Since	 PGC1α	 is	 	 known	 to	 cooperate	 with	 Peroxisome	 Proliferator-Activated	
Receptor	 α	 in	 the	 regulation	 of	 mitochondrial	 biogenesis	 [21,22],	 this	 further	 tighten	 the	 link	
between	mitochondria	 and	 lysosomes,	with	different	pathways	 and	molecular	mechanisms	 that	
regulate	the	relationship	between	the	two.	
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Interestingly,	two	recent	studies	also	showed	that	primary	mitochondrial	dysfunction	could	induce	
lysosomal	dysfunction	[23,24].	 Indeed,	T	cells	from	mice	deficient	 in	mitochondrial	transcription	
factor	A	(TFAM),	were	found	to	present	mitochondrial	defects	and	decreased	respiration;	this	was	
associated	with	 increased	nuclear	 translocation	of	TFEB,	weaker	 lysosomal	calcium	mobilization,	
reduced	 lysosomal	 enzyme	 activity	 and	 sphingomyelin	 accumulation,	 which	 are	 all	 relevant	
parameters	 for	 the	 evaluation	 of	 lysosomal	 function	 [23].	 Similarly,	 abnormal	 lysosomes	 were	
observed	 in	neurons	and	brains	 from	mice	 lacking	the	mitochondrial	protein	apoptosis	 inducing	
factor	(AIF)	[24].	Moreover,	in	mouse	embryonic	fibroblasts	(MEFs)	from	Optic	Atrophy	Protein	1	
(OPA1)	 knockout	 mice	 for	 (a	 protein	 involved	 in	 the	 regulation	 of	 mitochondrial	 cristae	
morphology),	accumulation	of	 lysosomes,	dysregulation	of	 lysosomal	pH,	as	well	as	decreased	in	
the	activity	of	the	lysosomal	enzyme	cathepsin	B	were	observed	[24].	The	lysosomal	defects	were	
at	 least	 partially	 rescued	 using	 antioxidant	 naturally	 present	 in	 cells	 like	 N-acetylcysteine	 or	
Coenzyme	 Q10to	 treat	 cells	 in	 culture,	 suggesting	 that	 increased	 free	 radical	 generation	 from	
damaged	mitochondria	might	mediate	altered	 lysosomal	biology	 [24].	Collectively,	 these	 studies	
have	suggested	a	link	between	mitochondrial	and	lysosomal	function,	but	whether	this	represents	
a	reciprocal	crosstalk	remains	to	be	determined.	
Interestingly,	one	of	the	signaling	pathways	involved	in	the	activation	of	autophagy	–	the	mechanism	
that	allow	cells	to	degrade	and	recycle	dysfunctional	and	unneeded	cellular	components	--	(see	Box	
4),	 AMP-activated	 protein	 kinase	 (AMPK)	 pathway,	 is	 regulated	 by	 the	 AMP/ATP	 ratio	 and	 by	
calcium	 levels	 [25].	 In	particular,	ATP	depletion	or	 increased	cytosolic	calcium	concentration	can	
both	activate	AMPKα.	This	in	turn	inhibits	mechanisticTarget	Of	Rapamycin	(mTOR),	activating	the	
lysosomal	and	autophagy	master	regulator	TFEB,	and	inducing	autophagy	in	human	immortalized	
cell	lines	and	in	mouse	models		[26–28].	These	findings	lend	further	support	to	the	tightly	integrated	
connection	between	mitochondrial	and	lysosomal	function.	The	functional	interplay	between	these	
organelles	might	also	be	facilitated	by	a	spatial	dialogue,	coordinating	the	localization	and	trafficking	
of	these	structures.	In	fact,	it	was	recently	shown	that	the	changse	in	the	expression	level	of	the	
protein	RAB26	are	responsible	for	the	relocalization	of	lysosomes	in	a	secretory	pancreatic	cell	lines	
that	in	turn	leads	to	changes	in	mitochondria	localization[29].		
Studies	of	lysosomal	and	mitochondrial	biology	support	the	hypothesis	that	lysosomal	dysfunction	
negatively	 affects	 mitochondrial	 function,	 and	 vice	 versa.	 However,	 even	 if	 a	 strong	 reciprocal	
interconnection	 between	 lysosomal	 and	 mitochondrial	 function	 exists,	 dissecting	 the	 specific	
mechanisms	by	which	these	affect	each	other	remains	challenging.	
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Mitochondrial	Impairment	in	LSDs	
All	the	LSDs	described	in	Box	1	present	some	form	of	mitochondrial	dysfunction	associated	with	a	
primary	 lysosomal	 impairment,	 (summarized	 in	 Table	 1),	 affecting	 the	 CNS	 and	 other	 tissues,	
suggesting	 that	 impaired	mitochondrial	 function	may	be	a	common	pathogenic	 feature	of	 these	
disorders.	However,	the	degree	and	nature	of	the	mitochondrial	damage	reported	vary	considerably	
depending	on	experimental	models	used.		
Morphological	 changes	 have	 been	 the	 easiest	 to	 detect,	 mainly	 through	 transmission	 electron	
microscopy	(TEM)	and	fluorescence	imaging	microscopy	(see	examples	in	ref.	[11]	and	[30]),	which	
mostly	reveal	an	abnormal	mitochondrial	network,	i.e.	mitochondrial	fragmentation	or	elongation.	
These	 abnormalities	 are	 in	 most	 cases	 associated	 with	mitochondrial	 bioenergetic	 dysfunction,	
quantified	 as	 a	 reduced	 mitochondrial	 membrane	 potential	 and/or	 impaired	 mitochondrial	
respiration.		
In	neurons	and	astrocytes	from	a	mouse	model	for	neuropathic	GD	[11]	and	in	fibroblasts	from	GD	
patients	 [31],	 mitochondria	 have	 been	 shown	 to	 be	 small	 and	 fragmented,	 exhibiting	 reduced	
membrane	potential	,	mitochondrial	complex	levels	and	activity,	as	well	as	impaired	respiration.		
Experimental	models	 of	Niemann	Pick	disease	C	 (NPC)	 also	present	 alterations	 in	mitochondrial	
morphology	and	 function	 (Box	1).	 In	yeast	 cells	 lacking	Ncr1p,	an	orthologue	of	 the	mammalian	
protein	Niemann	Pick	C1	 (NPC1,	 an	 intracellular	 cholesterol	 transporter	whose	mutations	 cause	
NPC),	 mitochondria	 are	 fragmented,	 and	 both	 mitochondrial	 membrane	 potential	 and	 oxygen	
consumption	rate	are	reduced	[32].	Two	independent	studies	of	fibroblasts	from	patients	carrying	
mutations	in	NPC1	gave	conflicting	results:	one	described	disruption	of	the	mitochondrial	network,	
but	increased	mitochondrial	mass	corresponding	to	increased	oxygen	consumption	[33].	The	other	
study	reported	reduced	mitochondrial	membrane	potential	but	no	effect	on	mitochondrial	mass	or	
morphology	 [34].	Neurons	derived	 from	NPC1	knockdown	human	Embryonic	 Stem	Cells	 (hESCs)	
showed	 accumulated	 fragmented	 mitochondria	 and	 mitochondrial	 proteins,	 without	 any	
measurable	 change	 in	 	 mitochondrial	 membrane	 potential	 [35].	 These	 latest	 findings	 were	 in	
agreement	with	those	from	NPC1	knockout	(KO)	mice,	in	which	neurons	presented	smaller	rounded	
mitochondria	with	reduced	membrane	potential,	decreased	ATP	synthase	activity	and	reduced	ATP	
generation	[36].		
A	mouse	model	of	Multiple	Sulfatase	Deficiency	(MSD)	generated	by	knocking	out	Sumf1,	which	
encodes	 for	 the	 protein	 Sulfatase-modifying	 factor	 1,	 involved	 in the pathway of sulfatase 
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oxidation,	was	again	associated	with	mitochondrial	fragmentation,	accumulation	of	dysfunctional	
mitochondria	 and	 impaired	 ATP	 production	 in	 brain	 and	 liver[37,38]	 (Box	 1).	 Fragmented	 and	
circular	 mitochondria	 with	 reduced	 membrane	 potential	 were	 also	 observed	 in	 neurons	 and	
astrocytes	 cultured	 from	 a	 GM1-gangliosidosis	 mouse	 model	 (Box	 1)	 [39].	 Degenerating	 and	
electron	dense	mitochondria	were	observed	using	TEM	in	brain	tissues	from	Hexb−/−	mice,	a	model	
of	 GM2-gangliosidosis	 (Box	 1)	 through	 knock-out	 the	 beta-hexosaminidase	 subunit	 beta	
(responsible	for	the	degradation	of	GM2	gangliosides)	 [30].	Moreover,	 in	neurons	from	a	mouse	
model	 for	Mucopolysaccaridosis	 III	 (MPS-III)	 type	C	 (Box	1),mitochondria	appeared	 swollen,	 and	
activity	 of	 the	 respiratory	 complexes	 II	 and	 IV	 were	 reduced,	 while	 expression	 levels	 of	 the	
Coenzyme	Q	protein,	a	component	of	the	electron	transport	chain,	were	also	reduced	[40].	
Earlier	 reports	 suggested	 that	 mitochondrial	 morphology	 and	 function	 are	 damaged	 in	 animal	
models	 for	 Neuronal	 Ceroid	 Lipofuscinosis	 (NCL)	 [41,42].	 More	 recently,	 it	 was	 shown	 that	
mitochondrial	 cristae	 were	 reduced	 and	 disorganized	 in	 human	 iPSC-derived	 neurons	 for	 NCL	
induced	 by	 CLN3	mutations	 [43],	 were	 elongated	 in	 cerebellar	 precursor	 cells	 in	 a	 Cln3Δex7/8	
knock-in	mice	[44],	and	showed	no	structural	alterations	(apart	from	some	smaller	mitochondria)	
in	primary	cultures	from	Cln3-/-	mouse	neurons,	in	which	oxygen	consumption	was	nevertheless	
decreased	[45].	Moreover,	mitochondria	were	depolarized	in	a	lymphoblast	model	of	CLN3	NCL	[46].	
When	considering	fibroblasts	from	NCL	patients	carrying	CLN1	and	CLN6	mutations,	mitochondria	
were	fragmented	and	redistributed	at	the	cell	periphery,	with	 increased	expression	 levels	of	the	
voltage-dependent	 anion	 channel	 (VDAC)	 and	 complex	 IV,	 consistent	 with	 accumulation	 of	
mitochondria	[47].		
Progressive	 neuronal	 injury	 (especially	 in	motor	 neurons)	 was	 found	 in	 Pompe	 disease	 (Box	 1)	
patients	and	models	[48,49].	This	evidence,	the	fact	that	other	tissues		(such	as	muscles)	in	Pompe	
disease	present	abnormal	mitochondrial	cristae	and	glycogen	accumulation	in	the	organelle	[50],	
and	 that	mitochondrial	membrane	 potential,	mitochondrial	 respiration	 and	 ATP	 production	 are	
reduced	in	muscle	cells	from	an	acid	α-glucosidase	(Gaa)	knockout	mouse	model	[51],	suggests	that	
mitochondrial	abnormalities	may	be	also	present	and	contribute	to	neuronal	damage.		
Some	 of	 the	 published	 work	 exploring	 mitochondrial	 function	 in	 relation	 to	 the	 LSDs	 remains	
contradictory,	with	conflicting	measurements	of	mitochondrial	membrane	potential,	mitochondrial	
mass	and	morphology	and	mitochondrial	respiration.	The	variations	in	findings	may	depend	on	the	
methods	 or	models	 used,	 and	 greater	 consistency	may	 be	 achieved	 through	 standardization	 of	
methodology	 for	 the	 systematic	 characterization	 of	 mitochondrial	 function	 [52].	 Thus,	 while	
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mitochondrial	 involvement	 in	 the	 pathophysiology	 of	 the	 LSDs	 is	 increasingly	 clear,	mechanistic	
details	 still	need	 to	be	clarified.	 Ideally,	appropriate	models	 for	 the	different	diseases	should	be	
selected	to	consider	the	specific	tissues	that	are	affected	in	the	disease,	and	in	particular	classes	of	
neurons	when	trying	to	explain	neurological	and	neurodegenerative	symptoms.	Live	cell	 imaging	
systems	should	be	used	to	characterize	mitochondrial	membrane	potential	(using	mainly	TMRM	or	
Rhod123	 dyes),	whilst	 also	 providing	 quantifiable	 data	 on	mitochondrial	morphology	 and	mass.	
Otherwise,	 immunocytochemical	 methods	 to	 label	 cells	 using	 antibody	 against	 mitochondrial	
protein	(such	as	Stress-70	protein	-	grp75	–	or	mitochondrial	import	receptor	subunit	TOM20)	could	
be	used	to	assess	mitochondrial	morphology	and	mass.	In	both	cases,	a	relatively	inert	cytosolic	dye	
such	as	calcein	(in	living	cells)	or	an	antibody	against	a	cytosolic	protein	(for	immunofluorescence	of	
fixed	material)	should	be	used	to	evaluate	the	cell	volume,	allowing	expression	of	mitochondrial	
mass	as	a	relative	volume	fraction.		
Mitochondrial	oxygen	consumption	should	be	measured,	using	the	fluorescence-based	‘Seahorse’	
or	MitoXpress	(Luxcel)	 	systems	[53]	or	a	more	classical	platinum	based	Clark	electrode	(e.g.	the	
Oxygraph	 2K,	 Oroboros)	 instruments,	 either	 using	 purified	mitochondria	 or	 intact	 cells.	 Indirect	
measurement	of	mitochondrial	respiration	level	can	be	obtained	by	evaluating	the	expression	levels	
or	the	activity	of	the	mitochondrial	respiratory	chain	complexes.		
Systematic	studies	of	mitochondrial	fission	and	fusion	in	LSDs,	are	few	and	far	between,	despite	the	
widely	 described	 profound	 changes	 in	 mitochondrial	 morphology.	 Indeed,	 the	 functional	
significance	 of	 altered	 mitochondrial	 morphology	 is	 not	 yet	 clear.	 When	 mitochondrial	
fragmentation	 in	 primary	 neurons	 from	 a	GD	mouse	model	was	 rescued	 by	 overexpressing	 the	
dominant-negative	 fission	 mediator	 GFP-Drp1K38A.	 This	 is	 a	 mutant	 of	 the	 GTPase	 Dynamin-
Related	Protein	1	(Drp1)	which	is	defective	in	GTP	binding,		causing	reduced	mitochondrial	fission	
and	therefore	mitochondrial	elongation.	Mitochondrial	function	was	unaffected	by	this	change	in	
morphology,		[11]	showing	that	mitochondrial	fragmentation	was	a	consequence	and	not	a	cause	
of	mitochondrial	dysfunction.	It	would	be	interesting	to	determine	whether	the	same	phenomenon	
applies	to	other	LSDs.		
Another	 important	 aspect	of	mitochondrial	 biology	 is	mitochondrial	 trafficking,	 especially	 in	 the	
CNS.	Mitochondrial	transport	to	regions	of	the	cell	where	ATP	demand	is	high	needs	to	be		finely	
tuned,	especially	in	large	cells	with	long	processes	such	as	neurons,	where	energy	consumption	may	
be	 highest	 at	 remote	 outposts	 [54,55].	 The	 Ca2+	 buffering	 capacity	 of	 mitochondria	 in	 specific	
cellular	 regions	 also	 has	 important	 implications	 for	 neuronal	 function	 by	 controlling	 the	
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spatiotemporal	patterning	of	intracellular	Ca2+	signaling	[54].	Mitochondrial	transport	mechanisms	
are	understudied	in	the	LSDs,	but	a	recent	study	reported	a	significant	reduction	in	the	number	of	
moving	mitochondria	 and	 in	 their	 speed	 in	 vitro	 in	 axons	 treated	 with	 psychosine,	 a	 lipid	 that	
accumulates	in	Krabbe	disease	[56].	
	
Causes	and	Consequences	of	Mitochondrial	Dysfunction	in	LSDs	
The	 specific	 molecular	 mechanisms	 that	 lead	 to	 neurodegeneration	 in	 LSDs	 remain	 poorly	
understood.	 Here,	 we	 consider	 candidate	 causes	 and	 consequences	 of	 mitochondrial	 damage	
associated	 with	 primary	 lysosomal	 dysfunction	 (see	 Figure	 1,	 Key	 Figure).	 A	 schematic	
representation	of	 the	 interplay	between	 lysosomal	dysfunction	and	mitochondrial	dysfunction	 is	
shown	in	Figure	1,	where	the	contribution	of	autophagy	impairment,	ROS	production	and	calcium	
homeostasis	dysregulation	is	also	presented.	
Ultimately,	it	seems	critical	to	establish	i)	whether	there	is	a	common	molecular	mechanism	that	
culminates	in	mitochondrial	dysfunction	in	LSDs;	ii)	the	extent	to	which	mitochondrial	dysfunction	
contributes	 to	 the	 disease	 phenotype	 and	 iii)	 whether	 the	 pathways	 leading	 to	 mitochondrial	
dysfunction	represent	viable	potential	therapeutic	targets.		
	
Impaired	Autophagy	and	Mitophagy	
Dysregulation	 of	 autophagic	 lysosomal	 pathways	 has	 been	 described	 in	 most	 of	 the	 lysosomal	
storage	disorders	we	consider	here	[11,31,35,37–40,50,57–60,51].	Most	of	these	LSDs	also	show	
fragmentation	and	a	loss	of	mitochondrial	membrane	potential	(as	previously	described),	which	is	
a	prerequisite	for	mitochondrial	removal	through	PINK1/Parkin-mediated	mitophagy	[61,62]	(Box	
5).	 The	 most	 extensively	 described	 pathway	 for	 mitophagy	 is	 triggered	 by	 the	 reduction	 of	
mitochondrial	membrane	potential	below	a	threshold	which	favors	the	accumulation	of	the	protein	
PTEN	 Induced	Putative	Kinase	1	 (PINK1)	at	 the	outer	membrane	of	damaged	mitochondria.	This	
recruits	 the	 E3	 ubiquitin-protein	 ligase,	 Parkin,	 which	 ubiquitinates	 proteins	 at	 the	 outer	
mitochondrial	membrane.	 	 Parkin-ubiquitinated	mitochondria	 recruit	 optineurin	which	 can	 bind	
Microtubule-associated	 protein	 1A/1B-light	 chain	 3	 (LC3),	 triggering	 autophagosome	 formation	
around	mitochondria,	and	promoting	the	removal	of	dysfunctional	organelles	 [63–65].	However,	
other	mitophagy	pathways	based	on	Outer	Mitochondrial	Membrane	localized	mitophagy	receptors	
whose	regulation	occurs	through	their	phosphorylation	were	recently	characterized,	as	well	as	lipid-
mediated	 mitophagy	 [66],	 while	 autophagy	 can	 also	 be	 triggered	 by	 increased	 free	 radical	
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generation	[67].	No	information	on	these	alternate	mitophagy	pathways	in	LSDs	are	available	at	the	
moment	and	more	 studies	will	be	needed	 to	clarify	 their	 relevance	 in	 the	etiopathogenesis	and	
progression	of	these	diseases.	
The	PINK1/Parkin	pathway	has	been	most	 intensively	 studied	 in	 relation	 to	PD,	 as	mutations	of	
PINK1	or	PARK2,	which	encodes	for	parkin,	are	genetic	causes	of	early	onset	PD.	Specific	impairment	
of	mitophagy	through	impaired	Parkin/Pink1	recruitment	or	function	has	also	been	investigated	in	
relation	to	GD	and	MSD	in	mouse	models.	In	primary	neurons	cultured	from	a	GD	mouse	model,	
colocalization	of	autophagosomes	and	mitochondria	was	reduced,	suggesting	reduced	recycling	of	
damaged	mitochondria	[11].	However,	mitochondria	in	GD	neurons	retained	the	capacity	to	recruit	
Parkin	 following	 treatment	 by	 a	 mitochondrial	 uncoupler	 --	 carbonyl	 cyanide	 4-
(trifluoromethoxy)phenylhydrazone,	 FCCP	 --,	 which	 transports	 hydrogen	 ions	 through	
mitochondrial	membranes	leading	to	collapse	of	the	mitochondrial	membrane	potential	(ucoupling	
respiration	 from	 oxidative	 phosphorylation),	 suggesting	 that	 the	 Parkin-mediated	 mitophagy	
pathway	was	 functional.	On	the	other	hand,	 in	GD	neurons,	under	basal	conditions,	depolarized	
mitochondria	did	not	 recruit	Parkin,	 suggesting	 that	mitochondrial	membrane	potential	was	not	
sufficiently	compromised	to	trigger	mitophagy	through	PINK1	accumulation.	Conversely,	a	study	of	
GD	 human	 fibroblasts	 showed	 increased	 co-localization	 between	 mitochondria	 and	
autophagosomes	[31],	suggesting	that	differences	may	arise	from	the	use	of	different	experimental	
models,	not	only	because	mouse	neurons	and	human	fibroblasts	were	used,	respectively,	but	also	
because	in	the	first	case	the	cells	completely	lack	the	enzyme,	while	in	the	second	case	fibroblasts	
carry	single	point	mutations	that	cause	a	loss	of	enzyme	folding,	expression	and	activity,	but	not	its	
complete	depletion.	In	MSD	mouse	liver	(but	not	brain),	the	expression	level	of	Parkin	was	reduced,	
relative	to	control	tissue.	However,	its	recruitment	to	mitochondria	upon	depolarization	to	trigger	
mitophagy	was	effective,	pointing	toward	a	tissue-specific	defect	in	Parkin	turnover	which	was	not	
seen	in	the	brain,	rather	than	toward	an	impairment	of	this	specific	mitophagy	pathway	[38].		
When	mitophagy	is	disrupted,	either	because	of	a	negative	feedback	mechanism	that	inhibits	the	
autophagic	pathway	upon	lysosomal	impairment,	or	through	dysfunctional	regulation	of	autophagy	
and	autophagolysosome	formation,	it	seems	plausible	that	impaired/defective	mitochondria	could	
accumulate	within	a	cell.	Dysfunctional	mitochondria	may	not	have	the	capacity	to	support	normal	
bioenergetic	 demands,	 and	 consequently,	 cell	 function	 might	 suffer.	 Furthermore,	 a	 damaged	
respiratory	chain	will	tend	to	generate	reactive	oxygen	species	(ROS)	at	an	increased	rate,	which	
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results	 in	 oxidative	 damage	 to	 proteins,	 lipids	 and	 DNA,	 a	 common	 feature	 of	 several	 LSDs	
[30,32,68–71].			
Macromolecules	and	protein	aggregates	can	also	accumulate	when	autophagy	is	impaired	and	this	
may	be	of	further	detriment	to	mitochondrial	function,	as	discussed	below.	
Oxidative	Stress	
ROS	are	highly	reactive	oxygen	radical	species	that	can	cause	oxidative	damage	to	proteins,	lipids	
and	 DNA.	 As	 an	 engine	 driven	 by	 redox	 and	 electron	 transfer	 reactions,	 the	 mitochondrial	
respiratory	 chain	 is	 one	of	 the	major	mechanisms	 generating	ROS	within	most	 cell	 types,	 often	
viewed	as	an	inevitable	by-product	of	oxidative	phosphorylation.	ROS	are	scavenged	by	antioxidant	
defences	which	 limit	 net	ROS	generation.	 In	healthy	 cells,	 low	 levels	 of	ROS	generation	may	be	
required	for	various	signaling	pathways	[72],	and	therefore,	the	balance	between	ROS	production	
and	 ROS	 scavenging	 must	 be	 finely	 tuned.	 An	 increase	 in	 net	 ROS	 generation	 exceeding	 the	
antioxidant	 scavenging	 capacity	 is	 defined	 as	 oxidative	 stress,	 leading	 to	 lipid	 peroxidation,	
oxidation	of	proteins	and	DNA	damage.			
Altered	rates	of	ROS	generation	have	been	reported	in	a	number	of	experimental	models	for	the	
LSDs.	 For	 instance,	 in	 patient	 derived	 NPC	 fibroblasts,	 ROS	 generation	 has	 been	 shown	 to	 be	
decreased	[33],	while	for	NCL	human	fibroblasts		--	associated	with	CLN2	and	CLN3	[58] --	and	GD	
human	 fibroblasts	 [31],	 production	 of	 superoxide	 and	 hydrogen	 peroxide	 were	 found	 to	 be	
increased.	In	different	studies	using	NCL	human	lymphoblasts	[46],	a	yeast	NPC	model	[32]	or	NPC	
human	fibroblasts[69],	a	human	oligodendryocyte	cell	line	exposed	to	psychosine	to	model	Krabbe	
disease	[73],	or	mytoubes	derived	from	a	knockout	mice	model	for	Pompe	disease	[51],	basal	ROS	
and/or	 H2O2	 production	 were	 also	 increased.	 Of	 note,	 increased	 protein	 oxidation	 and	 lipid	
peroxidation,	as	well	as	DNA	damage	due	to	oxidative	stress,	were	reported	in	the	urine,	plasma	
and	 leukocytes	of	MPS	 IV	patients	 [68],	 in	a	 yeast	NPC	model,	 in	NPC	human	 fibroblasts	and	 in	
different	NPC	mice	tissues	[32,69,70],	as	well	as	in	brain	tissues	of	GM2	gangliosidosis	mice	[30]	and	
in	NCL	patients	[71].	
Other	 models	 also	 showed	 increased	 vulnerability	 to	 H2O2-induced	 oxidative	 stress.	 Cerebellar	
neuronal	precursor	cells	derived	 from	the	Cln3Δex7/8	knock-in	mouse	model	showed	a	reduced	
survival	compared	to	control	when	treated	with	H2O2	in	concentration	ranging	from	50	to	200	μM	.	
An	NPC	yeast	model	treated	with	1.5	mM	H2O2	not	only	showed	decreased	cell	viability,	but	also	
increased	ROS	production,	protein	carbonylation	and	lipid	peroxidation	compared	to	control	cells	
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[32].	 Pompe	 disease	myotubes	 derived	 from	 a	Gaa	 knockout	mice	model	 showed	 a	 decreased	
viability	compared	to	control	when	treated	with	H2O2	up	to	2	mM	[51].		
In	human	GD	 fibroblasts	 and	gba1-/-	mice	neurons,	 Increased	ROS	production	or	mitochondrial	
dysfunction	 could	 be	 rescued	 when	 cells	 in	 culture	 were	 treated	 with	 mitochondria-targeted	
antioxidants	like	Coenzyme	Q		or	MitoQ,	respectively	[11,31],	consistent	with	a	mitochondrial	origin	
for	the	generation	of	ROS.	This	suggests	that	enhanced	oxidative	stress	or	increased	vulnerability	to	
it	may	be	a	feature	of	LSDs,	and	that	scavenging	mitochondrial	ROS	may	be	a	possible	therapeutic	
approach	to	consider.	
More	 in	 general,	 these	 various	 findings	 suggest	 that	 the	 balance	 between	 ROS	 generation	 and	
antioxidant	defence,	such	as	superoxide	dismutases,	catalase	and	glutathione,	may	be	disrupted	in	
several	 LSDs	and	 that	 in	 some	models,	 antioxidant	defences	may	be	defective	or	 inadequate	 to	
scavenge	 increased	 ROS	 generation.	 In	 NPC	 human	 fibroblasts,	 exhibiting	 decreased	 ROS	
production,	 decreased	 superoxide	 dysmutase	 1	 and	 2	 (SOD1	 and	 SOD2,	 responsible	 for	 the	
dismutation	of	superoxide	in	cell	cytoplasm	or	in	mitochondria,	respectively)	protein	expression	was	
observed	 [33].	 In	 contrast,	 in	 all	 other	models	 showing	 increased	ROS	production,	 the	 levels	 of	
antioxidant	 defences	 varied	 considerably.	 For	 instance,	 In	 MPS	 IV	 patient	 erythrocytes,	 the	
antioxidant	 glutathione,	 a	 tripeptide	 that	 reduces	 disulfide	 bonds	 formed	 within	 cytoplasmic	
proteins	and	is	therefore	oxidized	to	glutathione	disulfide,	was	decreased,	while	SOD	activity	was	
increased	 [68].	 	 In	 NCL	 human	 fibroblasts,	 the	 activity	 of	 the	 enzyme	 catalase,	 responsible	 for	
catalyzing	the	formation	of	water	and	oxygen	from	H2O2,	was	decreased	[58],	and	in	a	NPC	yeast	
model	and	 in	NPC	human	 fibroblasts,	SOD2	and/or	catalase	activity	and	glutathione	 levels	were	
decreased	[32,69],	while	SOD2	mRNA	and	protein	levels	were	reduced	in	GM2	gangliosidosis	mouse	
brains	[30]. Furthermore,	extensive	studies	of	oxidative	pathways	in	the	cerebellum	of	NPC	mouse	
models	[74]	as	well	as	from	post	mortem	material	from	NPC	patients	[75],	further	suggest	increased	
oxidative	stress	in	NPC.			
From	 the	 available	 evidence	 in	 the	 literature,	 it	 seems	 clear	 that	 oxidative	 stress	 is	 a	 common	
feature	 of	 different	 LSDs	 which	 is	 also	 a	 feature	 of	 other	 neurodegenerative	 disorders,	 and	 a	
possible	therapeutic	target.	However,	at	this	stage	the	contribution	of	mitochondrial	ROS	or	of	other	
ROS	 sources	 is	 still	 unclear,	 as	 well	 as	 the	 degree	 of	 dysregulation	 of	 the	 different	 antioxidant	
defences	 within	 mitochondria	 and	 in	 the	 cell	 cytoplasm.	 All	 these	 pathways	 deserve	 further	
systematic	investigations	in	LSDs.	
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Mitochondrial	Calcium	Dysregulation		
Considering	 the	 severe	 mitochondrial	 damage	 observed	 in	 many	 LSDs,	 it	 is	 not	 surprising	 that	
defects	 in	Ca2+	homeostasis	have	also	been	reported,	as	mitochondria	are	 intimately	 involved	 in	
calcium	 signaling,	 both	directly	 participating	 and	 also	providing	 the	 energy	 required	 for	 calcium	
signals	 to	 operate	 [76,77].	Moreover,	 lysosomal	 Ca2+	 is	 emerging	 as	 a	 significant	 contributor	 to	
global	cellular	Ca2+	signaling	[78].	In	addition,	lysosomes	can	regulate	their	own	refilling	via		ER	Ca2+	
stores	[79],	which	can	also	be	affected	in	LSDs	[80–82].	Lysosomal	calcium	stores	may	affect	global	
calcium	homeostasis,	further	impacting	on	mitochondrial	calcium	handling.	Moreover,	blockers	of	
inositol	triphosphate	receptors	(IP3R),	such	as	2-Aminoethoxydiphenyl	borate	and	Xestospongin-C,	
can	 induce	 the	 accumulation	 of	 Lysosomal-associated	membrane	protein	 1	 (LAMP1),	which	 is	 a	
lysosomal	protein,	similarly	to	the	accumulation		seen	in	LSDs,	further	linking	dysregulated	calcium	
homeostasis	to	pathogenic	mechanisms	in	these	diseases	[79].	
For	example,	mitochondrial	Ca2+	buffering	was	clearly	disrupted	in	neurons	from	Cln8mnd	mice	(NCL	
model)	[83].	In	this	study,	cellular	Ca2+	clearance	was	impaired	because	of	decreased	Ca2+	uptake	by	
mitochondria	 through	the	Mitochondrial	Calcium	Uniporter	 (MCU),	while	 the	plasma	membrane	
ATPase	 (PMCA)	 and	 the	 sarco/endoplasmic	 Ca2+	 ATPase	 (SERCA)	 were	 properly	 functioning.	
Moreover,	neurons	 showed	 increased	vulnerability	 to	excitotoxicity.	 In	another	 study,	 increased	
Ca2+	responses	to	glutamate	or	caffeine--	likely	due	to	increased	Ca2+	release	from	the	ER--	were	
observed	 in	 a	 pharmacological	 rat	 neuronal	 model	 of	 GD,	 leading	 to	 glutamate-induced	
excitotoxicity	[84].	The	machinery	that	allows	Ca2+	to	be	taken	up	by	mitochondria,	 i.e.	the	MCU	
complex,	 has	 not	 been	 studied	 at	 all	 in	 the	 LSDs.	 Interestingly,	 MCU	 expression	 controls	
excitotoxicity	 [85],	 further	highlighting	a	need	for	studies	 focused	on	the	MCU	complex	 in	 these	
diseases.	
With	regard	to	apoptotic	processes,	the	application	of	psychosine	to	neurons	in	vitro	was	found	to	
raise	 cytosolic	 calcium	 concentration,	 which	 was	 associated	 with	 transient	 mitochondrial	
membrane	hyperpolarization	followed	by	depolarization;	this	eventually	led	to	apoptosis	[73].	The	
accumulation	of	GM1	in	mouse	embryonic	fibroblasts	(MEFs)	from	beta-gal-/-	mice	(a	model	of	GM1	
gangliosidosis	 -	 Box	 1)	 also	 showed	 a	 significant	 increase	 in	 mitochondrial	 Ca2+	 concentration	
following	histamine	treatment	compared	to	control	MEFs	[86];	this	increase	was	sufficient	to	cause	
opening	of	the	mitochondrial	permeability	transition	pore,	a	mitochondrial	catastrophe	that	leads	
to	cell	death.	
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Conversely,	mitochondrial	Ca2+	uptake	was	reduced	 in	 fibroblasts	 from	patients	with	ML-IV	 [59];	
moreover	ML-IV	fibroblasts	treated	with	the		Ca2+-mobilizing	agonist,	bradykinin,	demonstrated	an	
increased	 apoptotic	 rate	 relative	 to	 controls	 [59].	ML-IV	 is	 caused	 by	mutations	 in	 the	 TRPML1	
channel	 which	 is	 involved	 in	 controlling	 lysosomal	 pH	 [87],	 regulating	 autophagy	 by	 sensing	
mitochondrial	 ROS	 production	 at	 the	 lysosomal	 membrane	 [88]	 in	 lysosomal	 adaptation	 upon	
starvation,	which	causes	a	rapid	change	in	TRPML1	activity	[89]	as	well	as	regulating	ER	Ca2+	release	
and	Ca2+	influx	[90].		Consequently,	unlike	GM1	gangliosidosis	models,	decreases	in	mitochondrial	
calcium	might	constitute	an	important	contribution	to	ML-IV	pathogenesis,	and	potentially	to	that	
of	 other	 LSDs.	 This	 is	 very	 interesting,	 because	 it	 clearly	 suggests	 that	 even	 if	 mitochondrial	
dysfunction	 is	 a	 common	 feature	 of	 LSDs,	 the	 contribution	 of	 this	 damage	 to	 the	 overall	 Ca2+	
signaling	 regulation	 can	 be	 different:	mitochondrial	 calcium	overload	 on	 one	 side,	 and	 reduced	
mitochondrial	calcium	uptake	on	the	other.	Further	studies	will	be	needed	to	clarify	the	mechanisms	
that	lead	to	one	or	to	the	other.		
At	 least	 in	NPC	models,	calcium	dyshomeostasis	seems	to	be	primarily	related	to	 lysosomal	Ca2+	
dysregulation.		Lysosomal	Ca2+	stores	can	be	assessed	by	tracking	either	Gly-Phe	b-naphthylamide	
(GPN)	levels	--	a	compound	which	is	degraded	by	cathepsin	C	and	causes	a	leak	of	Ca2+stores	from	
lysosomes--	 or	 bafilomycin	 A1--	 an	 inhibitor	 of	 the	 vacuolar-ATPase.	 	 Using	 Fura-2	 dye	 and	
fluorescence	imaging,	lysosomal	stored	Ca2+	was	found	to	be	decreased	in	lymphoblasts	from	NPC	
patients	 [91]	 and	 in	 human	 fibroblasts	 carrying	 a	 mutation	 in	 NPC1	 [34].	 However,	 ER	 and	
mitochondrial	calcium	content	remained		unaffected	in	NPC	lymphoblasts	[34].	It	was	also	recently	
shown,	by	using	a	caged-sphingosine	that	can	be	activated	by	light	exposure,	that	sphingosine	can	
trigger	 Ca2+	 release	 from	 lysosomes	 in	 human	 immortalized	 cell	 lines	 and	 this	 leads	 to	 TFEB	
activation	 [92].	 Interestingly,	 in	 NPC	 human	 fibroblasts	 sphingosine	 is	 accumulated	 and	 when	
uncaged	 by	 light	 trigger	 a	 smaller	 release	 of	 calcium	 from	 lysosomes,	 further	 suggesting	 that	
lysosomal	Ca2+	handling	is	crucial	for	the	etiopathogenesis	of	this	disease	[92].	Consequently,	it	is	
clear	that	more	work	is	needed	to	understand	the	effect	of	altered	lysosomal	Ca2+	signaling	on	global	
cellular	Ca2+	homeostasis	not	only	in	NPC	but	also	in	LSDs.		
Nevertheless,	it	is	clear	that	lysosomal	Ca2+	signaling,	ER	Ca2+	stores	and	mitochondrial	Ca2+	buffering	
capacity	are	crucial	pathways	in	the	etiopathogenesis	of	LSDs.	This	is	likely	due	to	the	interplay	in	
term	of	signaling	and	also	in	term	of	physical	contact	sites	among	mitochondria,	lysosomes	and	ER.	
Ca2+	 chelator,	 agonist/antagonist	 of	 Ca2+	 channels	 and	 other	 molecules	 able	 to	 regulate	 Ca2+	
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concentration	in	these	organelles	and	in	the	cytoplasm	and	Ca2+	release	or	uptake	from	them	may	
be	beneficial	in	LSDs	models	and	used	as	therapeutic	approaches.		
The	presence	of	storage	material	in	lysosomes,	the	alterations	in	membranes	composition	due	to	
changes	in	the	overall	lipid	contents	and	mitochondrial	damage	may	all	be	contributing	to	alteration	
in	 the	 Ca2+	 handling,	 but	 further	 causes	 are	 probably	 still	 unknown.	 Once	 elucidated,	 these	
mechanisms	may	also	be	target	for	designing	new	therapies.	
	
Accumulation	of	molecules	and	macromolecules	in	LSDs	
The	most	obvious	impact	of	lysosomal	impairment	in	LSDs	is	the	accumulation	of	macromolecules	
in	the	endo-lysosomal	compartment	and	cytoplasm.		
Amongst	 various	 macromolecules	 that	 can	 accumulate,	 the	 lipofuscins	 and	 lipofuscin-like	
aggregates	 are	 particularly	 interesting	 and	 important	 for	mitochondrial	 biology.	 Lipofuscins	 are	
yellow	 brown	 aggregates	 made	 up	 of	 oxidized	 cross-linked	 proteins	 and	 lipids	 that	 cannot	 be	
digested	by	cell	degradation	systems;	they	also	fluoresce	green	when	illuminated	with	blue	 light	
[93].	Lipofuscins	can	aggregate	under	physiological	and	pathological	conditions	in	different	tissues;	
for	example,	they	are	found	in	ageing	brains	but	their	accumulation	is	also	a	major	histopathological	
feature	of	a	number	of	LSDs	[94].		
Lipofuscin	granules	are	not	inert:	they	can	be	chemically	reactive	at	the	cell	surface,	binding	metals,	
and	driving	further	protein	and	lipid	oxidation	that	can	affect	lysosomal	and	proteasome	function	
[93].	Moreover,	remarkably,	one	of	the	main	constituents	of	lipofuscin	granules	is	the	ATP-synthase	
subunit	 c,	 especially	 in	 NCL	 across	 different	 species	 [43,44,57,95].	 This	 suggests	 a	 role	 for	
mitochondrial	damage	in	the	formation	of	lipofuscins	although	the	mechanism	by	which	the	protein	
is	singled	out	to	accumulate	in	these	structures	remains	obscure.	
Accumulation	 of	 alpha-synuclein	 (aS)	 and	 aS	 aggregates	 is	 another	 interesting	 and	 potentially	
important	feature	of	several	LSDs.	aS	is	a	protein	strongly	implicated	in	sporadic	and	genetic	forms	
of	PD	 that	normally	 localizes	primarily	 at	presynaptic	 terminals	 in	 the	mammalian	brain	 [96].	 In	
pathological	 conditions,	 aS	 tends	 to	 aggregate	 and	 form	 oligomers	 and	 amyloid	 fibrils	 that	
eventually	deposit	in	Lewy	Bodies	which	are	protein	and	lipid	aggregates	found	in	PD	and	in	other	
synucleinopathies	[97].	How	different	aS	species	contribute	to	the	disease	etiopathogenesis	is	still	
under	 debate,	 but	 interestingly	 aS	 accumulation	 and	 aggregation	 has	 been	 associated	 with	
mitochondrial	dysfunction	and	fragmentation	in	several	cellular	models	of	PD	[98–100].	However,	
it	is	currently	unclear	whether	aS	accumulation	is	a	primary	cause	of	mitochondrial	damage	in	those	
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models	or	has	a	secondary	effect	of	generating	ROS	production	and/or	impaired	autophagy.	Possible	
mechanisms	 previously	 reported	 include	 direct	 damage	 by	 aS	 oligomers	 at	 the	 mitochondrial	
membrane	 in	cells	and	neurons	overexpressing	the	protein	 [99,101]	or	secondary	effects	due	to	
altered	calcium	signaling	in	the	presence	of	aS	oligomers	[102]	or	to	autophagy	inhibition	caused	by	
aS	accumulation	in	the	cytoplasm	[103,104].	Although	speculative,	it	is	possible	that	a	mechanism	
such	 as	 this	 might	 also	 occur	 in	 certain	 LSDs,	 feeding	 into	 a	 vicious	 cycle	 to	 cause	 further	
accumulation	of	dysfunctional	mitochondria	when	quality	control	pathways	become	impaired.	
Indeed,	aS	aggregates	have	been	documented	in	a	number	of	LSDs	--	in	post	mortem	material	from	
brain	samples	of	patients	with	GD	[105],	and	GM2	gangliosidosis	[106].	Lewy	Bodies	were	also	noted	
in	the	brains	of	patients	with	NPC	[107]	while	neurons	in	the	brains	of	MPS	III	subjects	were	reactive	
for	phosphorylated	aS	[108].	aS	oligomers	were	also	found	in	the	plasma	of	patients	with	different	
LSDs,	including	GD,	NPC	and	Krabbe	disease	[109]	and	in	NPC	lymphoblasts	[110].	Many	LSD	rodent	
models	(for	GD,	NCL,	GM2	gangliosidosis,	MPS	III	and	MSD)	that	recapitulate	the	features	of	these	
diseases	 to	 a	 certain	 degree,	 also	 show	 aS	 accumulation,	 aggregation	 or	 overexpression	
[11,30,37,45].		
For	PD	and	for	all	other	neurodegenerative	disorders	presenting	aS	accumulation,	it	is	difficult	to	
define	 whether	 aS	 accumulation	 is	 a	 cause	 or	 an	 effect	 of	mitochondrial	 dysfunction,	 or	 both.	
However,	in	a	Hexb-/-	mouse	model	for	GM2	gangliosidosis,	silencing	aS	by	generating	double	knock	
out	mice	Hexb-/-		SNCA-/-	was	found	to	ameliorate	mitochondrial	function,	suggesting	that	aS	might	
contribute	to	mitochondrial	pathology,	at	least	in	this	model	[30].	
Metabolite	and	lipid	accumulation	are	a	common	feature	of	LSDs	and	lipids	seem	to	be	the	most	
interesting	in	relation	to	mitochondrial	deficiencies	because	of	their	role	as	structural	molecules	and	
as	signaling	molecules	as	well.	Dysregulation	of	sphingolipid	or	cholesterol	metabolism	are	features	
of	many	LSDs,	including	GD,	Krabbe,	NPC	and	NCL,	because	of	the	direct	impact	of	gene	mutations	
on	 constituents	 of	 lipid	 metabolism	 pathways	 in	 those	 diseases.	 With	 regard	 to	 mitochondrial	
dysfunction,	cholesterol	has	been	demonstrated	to	accumulate	in	the	mitochondria	of	NPC	human	
fibroblasts	 [33].	 Accordingly,	 the	 concentration	 of	 cholesterol	 in	 mitochondrial	 inner	 or	 outer	
membranes	 isolated	 from	 brain	 tissues	 of	 npc1-/-	 mice	 was	 increased	 compared	 to	 npc1+/-	 and	
npc1+/+	 mice	 [36].	 The	 activity	 and	 assembly	 of	 the	 electron	 transport	 complexes	 is	 critically	
dependent	on	the	 lipid	environment	 in	the	membrane,	but	the	specific	consequences	of	altered	
cholesterol	content	are	not	well	characterised.		
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In	an	MPS	III	mouse	model,	GM2	and	GM3	gangliosides	were	increased	in	total	brain	extracts	and	
their	 colocalization	 to	 mitochondria	 was	 verified	 by	 immunocytochemistry	 in	 brain	 slices	 using	
specific	antibodies	against	GM2-GM3	and	against	the	mitochondrial	marker	cytochrome	c	oxidase	
(complex	 IV)	 [40].	 In	 these	models,	 mitochondrial	 dysfunction	 was	 also	 observed,	 suggesting	 a	
mechanistic	link	between	lipid	accumulation	in	mitochondria	and	impaired	bioenergetic	function.	
More	 work	 is	 required	 to	 understand	 how	 the	 accumulation	 occurs,	 how	 it	 is	 responsible	 for	
mitochondrial	damage	and	how	it	can	be	prevented.	Moreover,	further	research	is	warranted	to	
determine	 whether	 the	 accumulation	 of	 lipids	 observed	 in	 other	 LSDs	 especially	 occurs	 in	
mitochondria.	
	
Concluding	Remarks		
The	 fact	 that	most	 of	 the	 neurological	 symptoms	 in	 the	 LSDs	 cannot	 be	 treated	with	 available	
therapies	 (see	 Box	 2	 and	 Box	 5)	 is	 of	 great	 concern.	 Given	 the	 fundamental	 importance	 of	
mitochondrial	 function	 in	 all	 tissues,	 but	 especially	 in	 neurons,	 the	 mechanisms	 that	 lead	 to	
mitochondrial	deficiencies	in	LSDs	deserve	more	attention.	Mitochondrial	fragmentation,	reduction	
in	 mitochondrial	 respiration	 and	 membrane	 potential,	 increased	 oxidative	 stress,	 as	 well	 as	
decreased	 calcium	 handling	 capacity	 in	 several	 different	 LSDs	 suggest	 that	 mitochondrial	
impairment	is	a	common	feature	of	LSDs.	It	is	of	special	interest	that	similar	impairments	are	also	
features	 of	 other	 major	 neurodegenerative	 disorders,	 suggesting	 common	 mechanistic	 links	 in	
neurodegenerative	pathways.	Similarities	and	differences	between	these	groups	of	diseases	need	
to	 be	 properly	 characterized	with	 the	 final	 aim	 of	 understanding	 their	 specific	 and/or	 common	
features,	 in	 order	 to	 pave	 the	 way	 to	 novel	 putative	 therapeutic	 strategies	 (see	 Outstanding	
questions	and	Box	2,5).		
Multiple	cellular	pathways	are	 impaired	 in	the	LSDs,	and	these	may	require	multiple	therapeutic	
approaches.	 Among	 several	 possibilities,	 targeting	 different	 regulatory	 pathways	 and	 employing	
strategies	aiming	to	improve	mitochondrial	function	in	combination	with	approaches	to	enhance	
autophagy	may	prove	to	be	beneficial	for	many	LSDs.	Indeed,	it	will	be	quite	exciting	to	follow	how	
future	mechanistic	insight	and	drug	development	unfold	in	the	fields	of	mitochondrial	biology	and	
LSDs.			
	
	
Box	1	–	Neurodegeneration	in	Lysosomal	Storage	Disorders	
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Gaucher’s	disease	(GD):	The	most	common	LSD	is	GD,caused	by	mutations	in	the	GBA	gene,	which	
encodes	 the	 lysosomal	 enzyme	 glucocerebrosidase	 (GCase),	 responsible	 for	 the	 cleavage	 of	
glucosylceramides.	GD	causes	a	broad	spectrum	of	phenotypes:	while	systemic	symptoms	such	as	
hepatosplenomegaly	 and	 bone	 abnormalities	 are	 usual	 and	 can	 be	 treated,	 no	 treatments	 are	
available	 for	 the	neurological	 symptoms,	which	 include	 seizures	and	brain	damage,	present	 in	a	
subset	of	patients.	The	most	severely	affected	children	survive	for	only	a	few	years.		
	
Niemann	Pick	disease	C	(NPC):	 is	caused	by	mutations	 in	NPC1,	a	gene	encoding	the	membrane	
protein	 NPC1	 that	 mediates	 intracellular	 cholesterol	 trafficking.	 Similarly	 to	 GD,	 patients	 show	
accumulation	of	harmful	 lipids	 in	different	tissues.	The	disease	primarily	affects	 liver,	spleen	and	
brain.	The	first	symptoms	appear	in	early	childhood	and	the	patients	survive	for	just	a	few	years	
after	diagnosis.	
	
Krabbe	 disease	 (also	 called	 globoid	 cell	 leukodystrophy):	 results	 from	 autosomal	 recessive	
mutations	 in	 galactocerebrosidase	 gene	 (GALC)	 cause,	 encoding	 for	 the	 lysosomal	 enzyme	
galactosylceramidase,	responsible	for	the	degradation	of	galacto-lipids	such	as	galactosyl-ceramide	
and	 galactosyl-sphingosine	 (also	 known	 as	 psychosine).	 GALC	 enzyme	 deficiencies	 lead	 to	
psychosine	 accumulation	 and	 progressive	 demyelination	 of	 cells	 in	 the	 nervous	 system.	 The	
symptoms	vary	but	include	deterioration	of	cognitive	and	motor	skills.	The	early	onset	forms	are	
fatal	before	age	2,	while	the	later	onset	forms	are	usually	milder	and	associated	with	a	longer	life	
expectancy.	
	
Mucopolysaccharidosis	 III	 (MPS-III,	 or	 Sanfilippo	 syndrome)	 is	 an	 autosomal	 recessive	 disease	
caused	 by	 deficiencies	 in	 different	 enzymes	 involved	 in	 heparan	 sulfate	metabolism,	 leading	 to	
accumulation	of	the	latter	in	lysosomes.	There	are	four	different	subtypes	(A,	B,	C	and	D)	caused	by	
mutations	 in	 different	 proteins	 (heparan	 N-sulfatase,	 N-acetyl-alpha-D-glucosaminidase,	 acetyl-
CoA:alpha-glucosaminide	acetyltransferase	and	 N-acetylglucosamine-G-sulfate	 sulfatase,	
respectively)	but	characterized	by	similar	severe	symptoms.	MPS-III	mainly	affects	the	brain	and	the	
spinal	 cord.	 Patients	 are	 asymptomatic	 at	 birth	 but	 develop	 neurological	 problems	 in	 early	
childhood.	 In	 particular,	 behavioral	 abnormalities	 are	 followed	 by	 intellectual	 deterioration	 and	
dementia,	and	life	expectancy	is	severely	reduced.		
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GM1	 and	 GM2	 gangliosidoses	 are	 major	 LSDs,	 caused	 by	 deficiencies	 in	 the	 enzymes	 beta-
galactosidase	 and	 beta-hexosaminidase,	 respectively,	 and	 characterized	 by	 the	 accumulation	 of	
gangliosides.	GM1	gangliosidoses	are	classified	depending	on	severity	and	age	of	onset	(infantile,	
junvenile	and	adult	forms).	Infantile	GM1	gangliosidoses	are	the	most	severe	and	show	very	severe	
neurological	 symptoms	 including	 developmental	 regression,	 seizures	 and	 profound	 intellectual	
disability.	 GM2	 gangliosidoses	 (also	 called	 Tay-Sachs	 and	 Sandhoff	 diseases,	 depending	 on	 the	
dysfunctional	enzyme	–	i.e.	hexosaminidase	A	or	B)	present	similar	characteristics;	affected	children	
lose	 motor	 skills,	 vision	 and	 hearing,	 develop	 seizures,	 and	 present	 intellectual	 disability	 with	
disease	progression.	For	both	infantile	GM1	gangliosidoses	and	GM2	gangliosidoses,	life	expectancy	
does	not	extend	beyond	early	childhood.	
	
Neuronal	 Ceroid	 Lipofuscinosis	 (NCL),	 or	 Batten	 disease,	 is	 often	 defined	 as	 a	 non-classical	
lysosomal	storage	disorder.	NCL	can	be	caused	by	mutations	in	12	different	genes	which	encode	
proteins	with	different	localizations	and	functions.	Each	one	of	these	NCL	forms	is	characterized	by	
lipofuscin	accumulation	and	symptoms	which	include	seizures,	visual	loss	and	progressive	mental	
impairment.	Classification	depends	on	disease	onset,	i.e.	infantile,	late	infantile,	juvenile	and	adult	
NCL,	and	life	expectancy	varies	with	the	NCL	form	and	symptoms.	
	
Other	LSDs,	that	impact	the	nervous	system	and	present	neurological	symptoms	include	multiple	
sulfatase	deficiency	(MSD),	caused	by	dysfunctions	in	the	protein	SUMF1,	located	in	the	ER	lumen,	
which	catalyzes	the	hydrolysis	of	sulfate	esters.	The	severity	of	MSD	can	vary,	and	it	 is	classified	
depending	 on	 the	 age	 of	 onset	 as	 neonatal,	 late-infantile,	 and	 juvenile.	Neurological	 symptoms	
include	movement	problems,	seizures	and	developmental	delay	(at	least	for	the	most	severe	types),	
while	other	symptoms	are	heart	problems,	skeletal	abnormalities	and	hepatosplenomegaly.	The	age	
of	onset	and	how	quickly	the	neurological	symptoms	worsen	determine	life	expectancy.		
	
Mucolipidosis	type	IV	is	caused	by	mutations	in	the	MCOLN1	gene,	encoding	a	lysosomal	membrane	
cation	channel	involved	in	calcium	signaling.	Symptoms	include	delayed	development	of	mental	and	
motor	skills,	hypotonia,	spasticity	and	visual	impairment.	A	minority	of	the	affected	individuals	has	
an	atypical	form	of	the	disease	with	milder	psychomotor	delay.	
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Pompe	 disease	 is	 caused	 by	 mutations	 in	 the	 gene	 encoding	 the	 lysosomal	 enzyme	 acid	 α-
glucosidase	(GAA),	which	converts	glycogen	to	glucose,	and	leads	to	glycogen	accumulation.	The	
main	symptoms	are	cardiomyopathy	and	muscle	weakness,	which	can	vary	depending	on	severity,	
and	in	most	cases	lead	to	respiratory	failure	and	death.		It	was	also	shown	a	relevant	damage	to	
central	nervous	system	and	in	particular	to	motor	neurons.		
	
Box	2	–	Therapeutic	Approaches:	Present	and	Future	
The	 main	 available	 treatments	 for	 LSDs	 rely	 on	 replacing	 the	 dysfunctional	 enzyme	 (enzyme	
replacement	therapy,	ERT)	or	restoring	enzyme	activity	[5].	However,	these	approaches	do	not	help	
with	 the	neurological	 symptoms	because	most	of	 these	molecules	 cannot	 cross	 the	blood	brain	
barrier.	Recent	advances	in	ERT	for	the	treatment	of	neuropathic	LSDs	were	achieved	by	fusing	the	
enzyme	 to	 peptides	 or	 proteins	 that	 increase	 brain	 delivery.	 Other	 options	 are	
intracerebroventricular	 injection	 or	 nanoparticle-mediated	 delivery	 of	 the	 enzymes.	 In	 vivo	
(systemic	or	CNS-directed)	or	ex	vivo	gene	therapy	are	also	under	evaluation	[111].		
	
Given	 the	 profound	 mitochondrial	 dysfunction	 described	 in	 some	 LSDs,	 treatments	 that	 affect	
mitochondrial	 function	may	prove	helpful	especially	 in	neurons.	 In	particular,	 it	seems	clear	that	
interventions	that	reduce	oxidative	stress	through	delivery	of	antioxidants	such	as	MitoQ	may	be	
beneficial	 [11,31].	 Other	 approaches	 might	 potentially	 target	 mitochondria,	 impacting	
mitochondrial	morphology,	improving	mitochondrial	respiration	to	restore	ATP	levels	or	modulating	
calcium	levels	or	handling.	
	
Accumulation	 of	 damaged	 mitochondria	 can	 also	 be	 harmful.	 Thus,	 strategies	 that	 enhance	
autophagy	might	prove	valuable,	bearing	in	mind	that	lysosomal	overload	is	not	desirable.	This	could	
be	achieved	by	 inhibiting	mTOR,	which	 successfully	 restored	ATP	 levels	 in	 iPSC-derived	neurons	
generated	from	a	patient	with	an	ATP	synthase	deficiency	[112],	or	by	acting	on	other	upstream	
pathways.	Another	strategy	may	involve	direct	manipulation	of	TFEB	activity	to	promote	autophagy	
and	 lysosomal	 biogenesis.	 Interestingly,	 TFEB	 was	 found	 to	 be	 predominantly	 localized	 in	 the	
nucleus	 in	MEFs	 from	MPS-II,	 MPS-III	 and	MSD,	 suggesting	 that	 the	 TFEB	 signaling	 pathway	 is	
activated	 in	 these	 diseases,	 probably	 in	 response	 to	 lysosomal	 stress	 [113].	 It	 remains	 to	 be	
determined	whether	further	activation	may	be	effective	in	removing	dysfunctional	mitochondria.	
	
	 20	
Another	approach	that	may	be	beneficial	concerns	the	targeted	removal	of	aS	aggregates,	which	
are	toxic	and	can	damage	mitochondria	[99];	this	might	be	potentially	achieved	either	by	enhancing	
autophagy	[114,115]	or	via	immunotherapy,	an	approach	that	has	been	effective	in	some	PD	models	
[116,117].	Nonetheless,	further	preclinical	studies	are	warranted	to	validate	these	possibilities.	
	
Box	3	Lysosome	Biology	
Lysosomes	are	organelles	enclosed	by	a	single	membrane	in	which	more	than	50	hydrolytic	enzymes	
break	 down	 macromolecules	 and	 organelles	 that	 cells	 target	 for	 degradation.	 Lysosomal	
degradation	 is	 essential	 to	 avoid	 the	 accumulation	 of	 damaged	 or	misfolded	 proteins	 or	 lipids,	
damaged	organelles	as	well	as	pathogens.	
	
The	optimal	pH	for	most	lysosomal	enzymes	is	acidic	[7].	An	acidic	pH	between	4.5	and	5	[87],	is	
achieved	within	lysosomes	by	the	proton-pumping	V-type	adenosine	triphosphatase	(ATPase)	[118],	
in	 concert	 with	 the	 chloride	 channel	 7	 (CIC-7),	 the	 nonselective	 cation	 channel	 mucolipin	 1	
(TRPML1),	the	two-pore	calcium	channels	(TPC1	and	TPC2)	and	the	potassium	channel	TMEM175	
[119–123].		
	
Hydrolytic	 enzymes	 are	 synthesized	 in	 the	 ER	 and	 Golgi	 and	 transferred	 to	 lysosomes	 through	
different	mechanisms	[124].	Substrates	destined	for	degradationd	within	lysosomes	are	delivered	
to	these	organelles	by	endocytosis	--	in	the	case	of	extracellular	material--	and	by	autophagy	--	for	
disposal	of	intracellular	waste	[125].	
	
It	was	long	thought	that	the	role	of	lysosomes	was	limited	to	the	degradation	of	substrates,	however	
this	view	has	now	changed	and	it	is	clear	that	these	organelles	are	involved	in	several	other	crucial	
processes	which	include	regulation	of	signaling	pathways,	calcium	signaling	as	well	as	energy	and	
nutrient	metabolism	[125,126].	
 
Lysosome	 biogenesis	 is	 regulated	 by	 the	 transcription	 factor	 EB	 (TFEB).	 TFEB	 activates	 the	
coordinated	lysosomal	expression	and	regulation	(CLEAR)	network,	which	enhances	the	expression	
of	lysosomal	genes,	increasing	the	number	of	lysosomes,	but	also	increasing	the	expression	of	other	
proteins	involved	in	lysosomal	cellular	clearance	mechanisms	such	as	autophagy	[26,113].	TFEB	is	
activated	by	Ca2+	release	from	lysosomes,	further	emphasising	a	central	role	of	 lysosomes	in	cell	
signaling	[126].	
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Box	4	Mitochondrial	biology	
Mitochondria	are	organelles	bound	by	a	double	membrane	that	provide	energy	to	eukaryotic	cells	
through	 oxidative	 phosphorylation.	 Mitochondrial	 respiratory	 complexes	 are	 redox	 proteins	
constituted	by	multiple	 subunits	 that	 generate	 and	maintain	 a	proton	gradient	 across	 the	 inner	
mitochondrial	membrane	 through	proton	pumping	 across	 the	 inner	membrane,	 and	 coupled	 to	
electron	 transfer.	 This	 process	 is	 driven	 from	Complex	 I	 through	 the	 oxidation	 of	NADH	 and	 at	
Complex	2,	by	the	oxidation	of	FADH2,	ultimately	transferring	electrons	to	molecular	oxygen	–	the	
basis	for	breathing	itself.	The	chemiosmotic	potential	generated	drives	the	ATP	synthase	(complex	
V)	 to	 phosphorylate	 ADP,	 generating	 ATP.	 A	 constitutive	 electron	 leak	 is	 always	 present	 during	
respiration	 and	may	 lead	 to	 the	 formation	of	 the	 free	 radical	 superoxide,	which	 can	 chemically	
interact	with	proteins	and	lipids	if	not	catabolized	by	enzymes	or	antioxidant	scavenging	molecules,	
such	as	superoxide	dismutase	(SOD)	or	glutathione.		
	
Mitochondria	are	also	involved	in	other	processes	including	the	regulation	of	apoptosis	and	calcium	
homeostasis.	This	is	particularly	important	for	neuronal	function	as	calcium	signaling	plays	a	central	
role	 in	 neuronal	 signaling.	 Mitochondrial	 Ca2+	 uptake	 shapes	 calcium	 signals	 in	 the	 cytoplasm	
through	a	transmembrane	protein,	a	 	Ca2+	selective	channel	 localized	at	 the	 inner	mitochondrial	
membrane,	termed	the	Mitochondrial	Calcium	Uniporter	(MCU)	[127].	The	MCU	mediates	calcium	
uptake	into	mitochondria,	which	regulates	not	only	cell	signaling	but	also	aerobic	metabolism	and	
cell	 death	 [128].	 MCU	 activity	 is	 tightly	 regulated	 by	 different	 interactors	 that	 form	 the	 MCU	
complex,	 including	 the	 Essential	MCU	 Regulator	 (EMRE)	 and	MICU1/MICU2	 proteins	 [129].	 The	
activity	of	the	complex	is	regulated	directly	by	the	concentration	of	cytosolic	calcium	to	which	it	is	
exposed.	Calcium	uptake	is	also	dependent	on	the	mitochondrial	membrane	potential,	i.e.	calcium	
accumulation	is	reduced	in	depolarized	mitochondria.		
	
Given	the	importance	of	mitochondrial	function	in	all	cell	types,	a	variety	of		mitochondrial	quality	
control	mechanisms	have	evolved	that	serve	to	remove	damaged	mitochondrial	proteins	or	even	
entire	 organelles	 through	 the	 ubiquitin	 proteasome	 system	 and	 via	 autophagic	 degradation	
[130,131].		
	
Box	4.	Autophagic	Mechanisms	
	 22	
	
Autophagy	 is	 a	 mechanism	 that	 allows	 the	 controlled	 and	 orderly	 removal	 of	 cellular	 waste,	
including	damaged	organelles	and	aggregated	proteins,	and	recycling	of	useful	cellular	components.		
	
Autophagy	 can	 be	 distinguished	 as	 macroautophagy,	 microautophagy	 and	 chaperone-mediated	
autophagy.	During	macroautophagy	(referred	to	as	‘autophagy’	in	this	review),	cytoplasmic	material	
is	sequestered	into	vesicles	enclosed	by	a	double	membrane,	termed	autophagosomes,	which	then	
fuse	with	lysosomes.	After	formation	of	the	autophagolysosomes,	lysosomal	enzymes	degrade	and	
recycle	autophagosome	cargo.		
	
Mitophagy	constitutes	a	type	of	autophagy	specific	to	the	removal	of	dysfunctional	mitochondria	
by	defined	pathways	 (mitochondrial	autophagy).	 It	 is	widely	 regarded	as	especially	 important	 in	
maintaining	 cell	 health,	 since	 for	 example,	 a	damaged	mitochondrial	 electron	 transport	 chain	 is	
more	likely	to	generate	excessive	free	radical	species	leading	to	oxidative	damage	in	a	host	cell.		
	
Microautophagy	 is	 a	 special	 type	 of	 autophagy	 in	 which	 cytoplasmic	 material	 is	 engulfed	 into	
lysosomes/vacuoles	by	membrane	invagination	and	then	degraded.		
Chaperone-mediated	autophagy	 is	a	process	of	degradation	of	 soluble	cytosolic	protein	 through	
their	targeting	to	lysosomes	by	a	chaperone-mediated	selection.		
	
Box	5.	The	Clinician’s	Corner		
• LSDs	account	for	most	neurodegenerative	disorders	in	children	but	no	effective	treatment	
for	the	neurological	symptoms	associated	are	available.	The	major	therapeutic	strategies	for	
systemic	symptoms	are	based	on	restoring	or	replacing	the	activity	of	a	given	dysfunctional	
enzyme,	 by	 using	 molecular	 chaperones,	 by	 providing	 the	 enzyme	 or	 by	 gene	 therapy.	
Inhibition	of	substrate	synthesis	is	also	possible.		
• Interesting	similarities	with	other	neurodegenerative	disorders	such	as	Parkinson’s	disease	
and	Alzheimer’s	disease	are	emerging:	in	particular,	similar	mechanisms	cause	mitochondrial	
dysfunction.	 Moreover,	 calcium	 dyshomeostasis	 and	 substrate/macromolecule	
accumulation	may	also	be	common	pathways	associated	with	the	etiopathogenesis	of	LSDs	
and	other	prevalent	neurodegenerative	disorders.	
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• LSDs	are	rare	diseases	each	of	which	presents	a	different	phenotype	for	reasons	that	are	still	
unclear.	 Therefore,	 the	 identification	 of	 common	 underlying	 targets	 as	 mitochondrial	
pathways	may	signpost	a	path	to	new	putative	therapeutic	approaches.	
	
Figure	legends	
Key	figure.	Figure	1.	Mechanisms	of	Mitochondrial	Dysfunction	in	LSDs.	
In	healthy	conditions,	mitochondria	are	responsible	for	producting	ATP	through	mitochondrial	
respiration	,	and	oxidative	phosphorylation,	a	process	that	leads	to	ROS	production.	ROS	levels	are	
controlled	by	antioxidant	defences	and	are	crucial	to	mantaining	cell	health.	Mitochondria	also	
manage	calcium	homeostasis	by	buffering	calcium	when	needed.		
In	LSDs,	dysfunctional	lysosomes	are	associated	with	impaired	autophagy,	and	therefore	impaired	
mitophagy.	This	can	lead	to	accumulation	of	dysfunctional	mitochondria	which	can	be	further	
damaged	by		accumulated	aggregates	or	macromolecules	such	as	alpha	synuclein.	Dysfunctional	
mitochondria	produce	ATP	less	efficiently	and	an	impaired	respiratory	chain	may	generate	more	
ROS,	while	damaged	mitochondria	have	a	reduced	capacity	to	buffer	calcium.	Impaired	calcium	
handling	may	also	be	associated	also	with	altered	ER	and	lysosomal	calcium	signaling.	
Aside	from	impaired	mitophagy,	other	molecular	mechanisms	leading	to	mitochondrial	
dysfunction	in	LSDs,	might	potentially	be	linked	to	the	relationship	between	mitochondria	and	
lysosomes.	
	
Table	1.	LSDs	and	Mitochondrial	Dysfunction	at	a	Glance.	
The	table	summarises	published	studies	on	mitochondria	biology	in	LSDs,	grouped	according	
to	the	experimental	approach	used	to	examine	changes	in	mitochondrial	function	and	the	models	
in	which	these	features	were	studied.	Findings	vary	depending	on	the	models	and	on	the	methods	
used,	suggesting	that	standardization	would	be	helpful	in	clarifying	the	role	of	mitochondrial	
dysfunction	in	LSDs	and	the	molecular	mechanisms	involved.	
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Resources	
The	Online	Metabolic	and	Molecular	Basis	of	 Inherited	Disease	(OMMIB)	 is	available	online	for	a	
more	 detailed	 description	 of	 the	 different	 LSDs	 described	 in	 this	 review	 (website:	
http://ommbid.mhmedical.com/book.aspx?bookid=971).	
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• Most	LSDs	show	profound	mitochondrial	dysfunction.	This	is	particularly	relevant	in	neurons	
which	have	a	strong	dependence	on	oxidative	phosphorylation	for	ATP	production	and	on	
fine-tuning	intracellular	calcium	levels	governing	neuronal	signaling.	
• Mitochondrial	 defects	 impact	 lysosomal	 function,	 suggesting	 a	 functional	 relationship	 –	
potentially	reciprocal	--	between	these	two	organelles.	
• Lysosomal	 dysfunction	 in	 LSDs	 is	 associated	 with	 impaired	 autophagy,	 dysregulation	 of	
mitochondrial	quality	control	pathways	as	well	as	accumulation	of	damaged	mitochondria.		
• Other	 new	 causes	 and/or	 consequences	 of	 mitochondrial	 dysfunction	 reported	 in	 LSDs	
include	increased	ROS	production	and	oxidative	stress,	calcium	dyshomeostasis.	
• Damage	mitochondria,	 calcium	 signaling	 and	 ROS	 unbalances	may	 all	 be	 targets	 for	 the	
development	of	new	therapeutic	strategies.	
• Alpha-synuclein	aggregation,	which	is	involved	in	neurodegeneration	in	Parkinson’s	disease,	
may	be	associated	with	mitochondrial	dysfunction	and	neurons	death	in	LSDs		
	
Outstanding	questions		
• How	does	a	primary	lysosomal	dysfunction	impair	mitochondrial	function?	
Most	LSDs	are	caused	by	mutations	in	lysosomal	proteins	which	lead	to	dysfunction	of	the	
autophagy	/lysosomal	pathway.	Mitochondrial	dysfunction	has	been	identified,	but	the	molecular	
mechanisms	by	which	lysosome	dysregulation	lead	to	mitochondrial	damage	are	still	unclear	and	
may	vary	according	to	the	specific	disease.	
• how	does	a	primary	mitochondrial	deficiency	impair	lysosomal	function?	
It	was	recently	shown	that	deficiencies	in	TFAM	or	mitochondrial	complexes	can	lead	to	lysosomal	
dysfunction	resembling	those	present	in	LSDs,	suggesting	a	link,	perhaps	reciprocal,	between	the	
two	organelles.	
• Are	defects	in	lysosomal	calcium	signaling	responsible	for	altered	mitochondrial	calcium	
handling?	
• 	Are	mitochondrial	defects	in	LSDs	primarily	due	to	downstream	deficiencies	in	mitochondrial	
quality	control	pathways	or	to	a	direct	effect	of	lysosomal	dysfunction	affecting	mitochondria?		
• To	what	extent	do	lysosome	storage	materials	in	different	LSDs	contribute	to	mitochondrial	
dysfunction?		
• Does	the	loss	of	products	normally	generated	by	lysosomal	degradation,	e.g.		sphingolipids,	
affect	mitochondrial	function?	
• What	are	the	common	or	specific	mechanisms	that	lead	to	mitochondrial	dysfunction	in	different	
LSDs	and	other	neurodegenerative	disorders?	LSDs	present	multiple	forms	of	mitochondrial		
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dysfunction:	some	are	shared	by	different	disorders	while	others	seem	to	be	more	specific.	
However,	the	reason	for	the	similarities	and	differences	have	not	been	explored	and	deserve	
careful	consideration.		
• could	mitochondria	be	effective	therapeutic	targets	to	treat	neurodegeneration	in	LSDs?	
Mitochondrial	fragmentation,	decreased	mitochondrial	membrane	potential,	calcium	
dyshomeostasis	and	increased	ROS	production	are	features	of	different	LSDs.	Consequently,	
thesemay	be	represent	putative	therapeutic	targets	to	treat	these	disoders.	
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